AstraZeneca Pharma India peers

Companies like AstraZeneca Pharma Indialatest year

Market cap and P/E at the last close; sales growth is the latest quarter on the same quarter a year before; ROE for the latest financial year.

Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

ASTRAZEN₹6,299.00

AstraZeneca Pharma India Limited

· Pharma & Health
₹ CrorePeersSANOFICONRPGHLSANOFISENORESINNOVACAPMOREPENLABIOLCPFDCMcap ₹15,748 Cr
Comp Set
In ₹ Crore except Per Share
Latest Annual
ASTRAZEN
FY26
SANOFICONR
FY26
PGHL
FY27
SANOFI
FY25
Peer
Average
Valuation — at last close
P/E83.98×33.26×95.19×◆ 17.77×48.74× +72%
P/B18.04×20.77×—◆ 8.52×14.65× +23%
EV/EBITDA58.39×24.60×—◆ 14.35×19.47× +200%
Market Cap₹15,748 Cr₹7,976 Cr₹9,152 Cr₹7,336 Cr₹8,155 Cr +93%
Growth
Revenue CAGR 3Y◆ 31.40%—-33.37%—-33.37% +194%
Revenue CAGR 5Y◆ 22.84%—-18.46%—-18.46% +224%
Net Income CAGR 3Y◆ 23.61%—-25.17%—-25.17% +194%
Revenue YoY (latest Q)◆ 29.73%12.48%7.37%-25.80%-1.98% +1599%
Net Income YoY (latest Q)-32.06%21.78%◆ 45.29%-33.70%11.12% -388%
Profitability
EBITDA Margin11.51%◆ 35.18%27.38%24.38%28.98% -60%
Net Income Margin8.24%◆ 27.33%26.44%20.53%24.77% -67%
Return on Common Equity22.82%◆ 73.09%—44.07%58.58% -61%
Return on Capital Employed25.62%◆ 82.66%—46.43%64.55% -60%
Return on Assets10.69%◆ 49.09%—24.85%36.97% -71%
Credit & Quality
Total Debt/Equity◆ 0.00×0.00×—0.00×0.00×
Interest Coverage51.99×148.65×◆ 668.43×302.73×373.27× -86%
Scale — latest FY
Revenue / Total Income₹2,276 Cr₹878 Cr₹364 Cr₹2,013 Cr₹1,085 Cr +110%
Net Income₹188 Cr₹240 Cr₹96.2 Cr₹413 Cr₹250 Cr -25%
Total Assets₹1,989 Cr₹547 Cr—₹1,612 Cr₹1,079 Cr +84%
EPS₹75.01₹104.27₹57.92₹179.46₹113.88 -34%
Book Value per Share₹349.12₹166.96—₹374.17₹270.57 +29%
◆ best value in the comp set per metric · Δ = subject vs average of the other companies.
« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.